ArriVent BioPharma (NASDAQ:AVBP) Earns “Outperform” Rating from Oppenheimer

ArriVent BioPharma (NASDAQ:AVBP)‘s stock had its “outperform” rating restated by research analysts at Oppenheimer in a note issued to investors on Friday,Benzinga reports. They currently have a $50.00 target price on the stock, up from their prior target price of $44.00. Oppenheimer’s price objective suggests a potential upside of 113.40% from the company’s current price.

A number of other brokerages have also recently weighed in on AVBP. Weiss Ratings reiterated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. Cantor Fitzgerald initiated coverage on shares of ArriVent BioPharma in a research note on Monday, December 22nd. They issued an “overweight” rating on the stock. Zacks Research raised shares of ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, December 5th. HC Wainwright raised their price target on ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a report on Friday. Finally, Truist Financial assumed coverage on ArriVent BioPharma in a research report on Tuesday, November 25th. They issued a “buy” rating and a $43.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.11.

ArriVent BioPharma Stock Down 7.2%

AVBP opened at $23.43 on Friday. ArriVent BioPharma has a 52 week low of $15.47 and a 52 week high of $27.22. The business’s 50 day moving average is $22.20 and its two-hundred day moving average is $20.93. The firm has a market cap of $967.19 million, a price-to-earnings ratio of -5.31 and a beta of 0.99.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.09. Equities analysts expect that ArriVent BioPharma will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On ArriVent BioPharma

A number of hedge funds have recently added to or reduced their stakes in AVBP. Infinitum Asset Management LLC increased its position in ArriVent BioPharma by 6.6% during the 4th quarter. Infinitum Asset Management LLC now owns 4,123,923 shares of the company’s stock worth $82,973,000 after purchasing an additional 255,000 shares during the period. Suvretta Capital Management LLC lifted its holdings in shares of ArriVent BioPharma by 10.9% in the 4th quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company’s stock valued at $82,613,000 after buying an additional 402,583 shares during the period. Vanguard Group Inc. lifted its holdings in shares of ArriVent BioPharma by 36.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company’s stock valued at $37,445,000 after buying an additional 545,991 shares during the period. State Street Corp boosted its stake in shares of ArriVent BioPharma by 6.3% in the fourth quarter. State Street Corp now owns 1,091,980 shares of the company’s stock valued at $21,971,000 after buying an additional 64,352 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of ArriVent BioPharma by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 753,519 shares of the company’s stock valued at $15,164,000 after buying an additional 37,231 shares in the last quarter. Institutional investors and hedge funds own 9.48% of the company’s stock.

Key ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.